Affiliations: [a] Laboratoire de Biochimie et Biologie Moléculaire, UF Oncologie-Endocrinologie-Neurobiologie, Hôpital Central, Centre Hospitalier Universitaire, Nancy, France
| [b] CMRR de Lorraine Hôpital de Brabois CHU Nancy, Vandoeuvre lès Nancy, Nancy, France
| [c] Unité ESPRI-BioBase, CHRU Nancy, Vandoeuvre lès Nancy, Nancy, France
| [d] UR AFPA–USC 340, Equipe BFLA, Université de Lorraine, Nancy, France
Correspondence:
[*]
Correspondence to: Dr. Catherine Malaplate-Armand, Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital Central, 29 avenue du Maréchal de Lattre de Tassigny – CO n° 34 – 54035 Nancy Cedex, France. Tel.: +33 3 83 852785; Fax: +33 3 83 851969; E-mail: [email protected].
Abstract: Background: Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers have recently been included in the criteria for AD diagnosis. Unfortunately, their wider use in routine and interpretation require more standardization, particularly for the pre-analytical steps. In particular, amyloid-β (Aβ)42 peptide measurement is strongly influenced by the type of collection tube and by repeated freeze/thaw cycles. Objective: The objectives of this study were to compare, in clinical setting, the impact of collection tubes and the repetition of freeze/thaw cycles on Aβ42 and Aβ40 concentrations and consequently determine if the Aβ42/Aβ40 ratio could resolve the diagnosis difficulties related to these pre-analytical parameters. Methods: CSF from 35 patients was collected in different polypropylene (PP) and stored at – 80°C after sampling. For CSF collected in the reference tube, three successive freeze-thaw cycles were done. Aβ42 and Aβ40 concentrations were determined in each condition in order to calculate the Aβ42/Aβ40 ratio. Results: Our results showed that CSF Aβ42 and Aβ40 values were significantly different according to the type of collection tube and the number of freeze/thaw cycles. Although the calculation of the Aβ42/Aβ40 ratio eliminated the effect of PP tube-dependent variation, this was not the case for freeze-thaw cycle-associated variation. Conclusion: The use of Aβ42/Aβ40 ratio rather than Aβ42 alone could contribute toward pre-analytical standardization, thus allowing the general use of CSF AD biomarkers in routine practice.
